TapewireFind a company

person · Reporting owner

Friedberg Ezra M

Disclosed activity across 2 companies

Tapewire entity
31625
SEC CIK
0001679440

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HUMANIGEN, INCKBIO · Entity 108862DirectorSeptember 13, 2016September 15, 2016
Pelthos Therapeutics Inc.PTHS · Entity 6798DirectorOctober 02, 2026October 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HUMANIGEN, INC

Report date September 13, 2016 · Filed September 15, 2016

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 · Expires 2026-09-12Direct100,000 Reported balance After 2016-09-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2016-09-13 · Grant · Acquired 100,000 · Balance 100,000

F1: The option vests and becomes exercisable in 12 equal quarterly installments beginning on December 13, 2016.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable in 12 equal quarterly installments beginning on December 13, 2016.

Pelthos Therapeutics Inc.

Report date October 02, 2026 · Filed October 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect80,484 Reported balance After 2026-10-02 transaction · row 1
1 source row

Row 1 · 2026-10-02 · Sale · Disposed 558 · Balance 80,484

F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

Common StockSEC Table I · non-derivativeIndirectBy Balmoral Financial Group LLC82,072 Reported balance Holding disclosure · report date 2026-10-02 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 82,072

F2: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Key Recovery Group LLC40,000 Reported balance Holding disclosure · report date 2026-10-02 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 40,000

F2: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F2: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 02, 2026 Filed Oct 6, 2026 21:53 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 558 $20.72 $11,560.03
Disclosure

SEC source: 0001919246-26-000130 · wk-form4_1791323632.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,484

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

Read SEC document
July 02, 2026 Filed Jul 7, 2026 21:03 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 24 $27.33 $655.81
Disclosure

SEC source: 0001919246-26-000102 · wk-form4_1783458235.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,042

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F3 · price: This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 02, 2026 Filed Jul 7, 2026 21:03 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 534 $26.03 $13,900.18
Disclosure

SEC source: 0001919246-26-000102 · wk-form4_1783458235.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,066

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 15, 2026 Filed Jun 17, 2026 21:25 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 59 $27.94 $1,648.48
Disclosure

SEC source: 0001919246-26-000093 · wk-form4_1781731506.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,600

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F3 · price: This transaction was executed in multiple trades at prices ranging from $27.92 to $28.00. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 15, 2026 Filed Jun 17, 2026 21:25 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 224 $27.12 $6,075.89
Disclosure

SEC source: 0001919246-26-000093 · wk-form4_1781731506.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,659

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F2 · price: This transaction was executed in multiple trades at prices ranging from $26.71 to $27.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 14, 2026 Filed May 18, 2026 22:11 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 Tax withholdingCommon Stock 144 $27.01 $3,889.01
Disclosure

SEC source: 0001919246-26-000073 · wk-form4_1779142269.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,883

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.00 to $27.0101. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 02, 2026 Filed Apr 6, 2026 21:03 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 265 $21.36 $5,660.72
Disclosure

SEC source: 0001919246-26-000054 · wk-form4_1775509382.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,027

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F3 · price: This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 02, 2026 Filed Apr 6, 2026 21:03 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 293 $20.51 $6,010.05
Disclosure

SEC source: 0001919246-26-000054 · wk-form4_1775509382.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,292

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 25, 2025 Filed Nov 26, 2025 17:37 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 2,000 $28.01 $56,010.00
Disclosure

SEC source: 0001753926-25-001831 · ownership.xml · nonDerivative · entry 4

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 30,000

F1 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
November 25, 2025 Filed Nov 26, 2025 17:37 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 1 $28.50 $28.50
Disclosure

SEC source: 0001753926-25-001831 · ownership.xml · nonDerivative · entry 3

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 32,000

F1 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
November 25, 2025 Filed Nov 26, 2025 17:37 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 2,000 $28.14 $56,270.00
Disclosure

SEC source: 0001753926-25-001831 · ownership.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 32,001

F1 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
November 25, 2025 Filed Nov 26, 2025 17:37 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 5,999 $28.00 $167,972.00
Disclosure

SEC source: 0001753926-25-001831 · ownership.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 34,001

F1 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
July 02, 2025 Filed Jul 8, 2025 01:42 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantStock Option · Derivative 58,230 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001753926-25-001104 · ownership.xml · derivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,230

Underlying: Common Stock · 58,230 shares

Expires 2035-07-02

F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.

F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.

Read SEC document
July 02, 2025 Filed Jul 8, 2025 01:42 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantRestricted Stock Units · Derivative 19,108 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001753926-25-001104 · ownership.xml · derivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,012

Underlying: Common Stock · 19,108 shares

Expires 2035-07-02

F1 · price: On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.

F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.

F3 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Read SEC document
July 02, 2025 Filed Apr 1, 2026 21:45 UTC Amendment Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantCommon Stock 19,108 $0.00 $0.00
Disclosure

SEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 3

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,585

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:05 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 ConversionSeries A Convertible Preferred Stock · Derivative 40,000 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 7

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Key Recovery Group LLC

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:05 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 ConversionSeries A Convertible Preferred Stock · Derivative 40,000 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 6

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:05 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 PurchaseSeries A Convertible Preferred Stock · Derivative 40,000 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 5

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Key Recovery Group LLC

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:05 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 PurchaseSeries A Convertible Preferred Stock · Derivative 40,000 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 4

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 40,000

Underlying: Common Stock · 92,072 shares

Expires not disclosed

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:05 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 ConversionCommon Stock 40,000 $10.00 $400,000.00
Disclosure

SEC source: 0001753926-25-001079 · ownership.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Key Recovery Group LLC

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:05 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 ConversionCommon Stock 40,000 $10.00 $400,000.00
Disclosure

SEC source: 0001753926-25-001079 · ownership.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
November 13, 2024 Filed Nov 15, 2024 21:19 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 GrantRestricted Stock Units · Derivative 24,533 Not disclosed Strike: $0.64 Not disclosed
Disclosure

SEC source: 0001753926-24-001947 · ownership.xml · derivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 634,752

Underlying: Common Stock · 24,533 shares

Expires 2024-11-13

F1 · price: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

F1 · derivative.exercise_date: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

Read SEC document
November 13, 2024 Filed Apr 1, 2026 21:45 UTC Amendment Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantCommon Stock 2,454 $0.00 $0.00
Disclosure

SEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,477

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Read SEC document
June 14, 2024 Filed Jun 19, 2024 00:03 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 GrantRestricted Stock Units · Derivative 64,498 Not disclosed Strike: $1.30 Not disclosed
Disclosure

SEC source: 0001753926-24-001133 · ownership.xml · derivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 610,219

Underlying: Common Stock · 64,498 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

Read SEC document
June 14, 2024 Filed Apr 1, 2026 21:45 UTC Amendment Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantCommon Stock 6,450 $0.00 $0.00
Disclosure

SEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,023

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:12 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 ConversionSecured Convertible Promissory Note · Derivative 33,136 Not disclosed Strike: $4.80 Not disclosed
Disclosure

SEC source: 0001753926-24-000372 · ownership.xml · derivative · entry 4

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Balmoral Financial Group LLC

Disclosed balance after: 0

Underlying: Common Stock · 6,992 shares

Expires 2024-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F3 · price: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).

Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:12 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 ConversionSecured Convertible Promissory Note · Derivative 65,513.61 Not disclosed Strike: $4.80 Not disclosed
Disclosure

SEC source: 0001753926-24-000372 · ownership.xml · derivative · entry 3

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Balmoral Financial Group LLC

Disclosed balance after: 0

Underlying: Common Stock · 13,649 shares

Expires 2024-02-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F2 · price: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).

Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:12 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 Exercise / conversionCommon Stock 6,992 $4.80 $33,561.60
Disclosure

SEC source: 0001753926-24-000372 · ownership.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Balmoral Financial Group LLC

Disclosed balance after: 520,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F3 · shares: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F3 · price: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).

Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:12 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 Exercise / conversionCommon Stock 13,649 $4.80 $65,515.20
Disclosure

SEC source: 0001753926-24-000372 · ownership.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Balmoral Financial Group LLC

Disclosed balance after: 513,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F2 · shares: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F2 · price: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).

Read SEC document
February 21, 2024 Filed Mar 12, 2024 20:05 UTC Amendment Pelthos Therapeutics Inc. CHRO · Entity 6798 PurchaseCommon Stock 16,667 $6.00 $100,002.00
Disclosure

SEC source: 0001753926-24-000518 · ownership.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 545,721

F1 · security: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

F1 · kind: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

F1 · shares: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

F1 · price: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

F1 · balance_after: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

Read SEC document
September 13, 2016 Filed Sep 15, 2016 17:38 UTC HUMANIGEN, INC KBIO · Entity 108862 GrantStock Option (right to buy) · Derivative 100,000 $0.00 Strike: $3.38 $0.00
Disclosure

SEC source: 0001123292-16-002730 · edgar.xml · derivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2026-09-12

F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal quarterly installments beginning on December 13, 2016.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.